ARTICLE | Clinical News

Picato ingenol mebutate gel regulatory update

January 20, 2014 8:00 AM UTC

Leo Pharma and Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband) agreed on a price for Picato ingenol mebutate gel to treat actinic keratosis. The price is not disclosed. In July 2013, Germany's Federal Joint Committee (G-BA) said Picato has "no additional benefit" over hyaluronic acid-containing diclofenac gel, a comparator requested by G-BA (see BioCentury, July 15, 2013). Drugs that do not have an additional benefit are added to the reference pricing system, which gives a similar base price to all comparable drugs. If there is no reference, the company will negotiate a price no higher than that of the comparator. ...